Can we personalize treatment for kidney diseases?
(17/1062)
(+info)
Information management to enable personalized medicine: stakeholder roles in building clinical decision support.
(18/1062)
(+info)
What is the role and impact of molecular markers on treatment decisions for colorectal cancer in the adjuvant setting?
(19/1062)
The new mantra for delivering optimal cancer treatment is "personalized care." This extends beyond the holistic to using germline and somatic tumoral mutations to link a specific therapy to some prognostic or predictive factor which defines a particularly responsive patient subgroup who might benefit most from treatment. Furthermore, inherited polymorphisms have the potential to greatly modulate the side effects of treatment, especially for chemotherapy which has a notoriously narrow therapeutic window. (+info)
Effect of age, weight, and CYP2C19 genotype on escitalopram exposure.
(20/1062)
(+info)
Institutional Profile: The University of California Pharmacogenomics Center: at the interface of genomics, biological mechanisms and drug therapy.
(21/1062)
(+info)
Heterogeneity of adenosine triphosphate-based chemotherapy response assay in colorectal cancer--secondary publication.
(22/1062)
(+info)
KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
(23/1062)
(+info)
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
(24/1062)
(+info)